Biopharma AI
ByCan Angelini’s $120M AI Alliance with Quiver Bioscience Redefine Drug Discovery in Genetic Epilepsies?
Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a multiyear collaboration with…
Is Takeda’s $1.7B Bet on Iambic Therapeutics the Defining Moment for AI-Validated Drug Discovery?
Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has entered a multiyear…
Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to a Unified Agentic AI Platform in Biopharma?
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
Top 10 Pharma Brands of 2025 — Sales Performance, Company Strategy & Market Outlook
The pharmaceutical market in 2025 was defined by high-value specialty brands delivering breakthrough outcomes in oncology, metabolic disease,…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
AI in Clinical Trials: Breakthrough Efficiency or Bottlenecked by Biology’s Chaos?
AI is slashing clinical trial timelines and costs where data flows freely—think 35-50% faster enrollment and 30% OpEx…
